A novel promising ADC for MM in clinic is the B-cell maturation antigen (BCMA)-targeted antibody, GSK2857916 (belantamab mafodotin), which is formed by a humanized IgG1 conjugated with a tubulin polymerization inhibitor, monomethyl auristatin F (MMAF). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.